Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S. Jansen MP, et al. Among authors: lardon f. Mol Oncol. 2015 Jun;9(6):1218-33. doi: 10.1016/j.molonc.2015.02.006. Epub 2015 Mar 4. Mol Oncol. 2015. PMID: 25771305 Free PMC article.
The interaction between ER and NFκB in resistance to endocrine therapy.
Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY, Van Laere SJ. Sas L, et al. Among authors: lardon f. Breast Cancer Res. 2012 Aug 31;14(4):212. doi: 10.1186/bcr3196. Breast Cancer Res. 2012. PMID: 22963717 Free PMC article. Review.
Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals Krüppel-like factor 9 as a potential suppressor of invasive growth in breast cancer.
Limame R, de Beeck KO, Van Laere S, Croes L, De Wilde A, Dirix L, Van Camp G, Peeters M, De Wever O, Lardon F, Pauwels P. Limame R, et al. Among authors: lardon f. Oncoscience. 2013 Jan 18;1(1):69-81. doi: 10.18632/oncoscience.10. eCollection 2014. Oncoscience. 2013. PMID: 25593984 Free PMC article.
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, Pauwels P, Peeters M, Vermorken JB, Wouters A. De Pauw I, et al. Among authors: lardon f. Mol Oncol. 2018 Jun;12(6):830-854. doi: 10.1002/1878-0261.12197. Epub 2018 May 1. Mol Oncol. 2018. PMID: 29603584 Free PMC article.
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A. Van den Bossche J, et al. Among authors: lardon f. Mol Oncol. 2019 May;13(5):1196-1213. doi: 10.1002/1878-0261.12477. Epub 2019 Apr 5. Mol Oncol. 2019. PMID: 30859681 Free PMC article.
151 results